Hutchison MediPharma Limited and Ortho-McNeil-Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson have formed a collaboration, taking advantage of MediPharma’s work on a novel inflammation/immunology target. MediPharma will continue its discovery and development activities through clinical proof-of-concept, unless OMJPI exercises an option to take over the development. If that happens, OMJPI will have exclusive rights to develop and commercialize the compounds. More details...

Stock Symbols: (AIM: HCM) (NYSE: JNJ)